Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s

Eli Lilly’s new obesity pill seems to be as effective as injected GLP-1s in helping patients lose weight, according to recent clinical trials.

The pill, known as Tirzepatide, works by mimicking the effects of naturally occurring hormones in the body that regulate appetite and metabolism.

Studies have shown that patients who took the pill lost an average of 12% of their body weight over a 40-week period.

This is a significant finding as obesity rates continue to rise globally, posing a serious health risk to millions of people.

GLP-1s are currently used as injectable medications for treating obesity, but the pill form may be more convenient for some patients.

The pill is still undergoing testing and has not yet been approved by regulatory agencies for widespread use.

Further research is needed to determine the long-term effects and safety of the pill.

If approved, this pill could provide a much-needed treatment option for the millions of people struggling with obesity.

Overall, the results of the trials are promising and offer hope for a new, effective treatment for obesity.